CXCL9 (74-103) (human) (trifluoroacetate salt)
(Synonyms: Chemokine (C-X-C motif) Ligand 9 (74-103),MIG30,Monokine Induced by Interferon-γ (74-103)) 目录号 : GC91864Chemokine (C-X-C motif) ligand 9 (CXCL9) (74-103) is a C-terminal fragment of mature CXCL9.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Chemokine (C-X-C motif) ligand 9 (CXCL9) (74-103) is a C-terminal fragment of mature CXCL9.[1] It binds to the glycosaminoglycan heparin in a cell-free assay (Kd = 3.1 nM).[2] CXCL9 (74-103) inhibits the binding of CXCL8 or CXCL11 to heparin, as well as chemokine (C-C motif) ligand 2 (CCL2) binding to heparan sulfate, in a concentration-dependent manner.[1] Unlike full-length CXCL9, CXCL9 (74-103) does not increase intracellular calcium levels in CHO cells expressing human CXC receptor 3 (CXCR3). CXCL9 (74-103) reduces the cytopathogenic effect of respiratory syncytial virus (RSV) in HeLa cells, herpes simplex virus 1 (HSV-1) in human embryonic lung (HEL) cells, and dengue virus serotype 2 in HMEC-1 cells (EC50s = 23, 15, and 11 µM, respectively).[2] It inhibits CXCL8 (1-77)- or monosodium urate-induced neutrophil extravasation to the tibiofemoral articulation in mouse models of acute inflammation or gout, respectively, when administered at a dose of 100 µg/animal.[1] CXCL9 (74-103) increases survival and decreases liver neutrophil infiltration and necrosis in a mouse model of liver injury induced by acetaminophen .[3] Intravenous administration of CXCL9 (74-103) (100 µl of a 1 mg/ml solution) decreases bronchoalveolar lavage fluid (BALF) neutrophil infiltration and IL-1β levels, but does not reduce lung bacterial burden, in a mouse model of K. pneumoniae-induced pneumonia.[4]
References:
[1].Vanheule, V., Janssens, R., Boff, D., et al.The positively charged COOH-terminal glycosaminoglycan-binding CXCL9(74-103) peptide inhibits CXCL8-induced neutrophil extravasation and monosodium urate crystal-induced gout in miceJ. Biol. Chem.290(35)21292-21304(2015).
[2].Vanheule, V., Vervaeke, P., Mortier, A., et al.Basic chemokine-derived glycosaminoglycan binding peptides exert antiviral properties against dengue virus serotype 2, herpes simplex virus-1 and respiratory syncytial virusBiochem. Pharmacol.10073-85(2016).
[3].Marques, P.E., Vandendriessche, S., de Oliveira, T.H.C., et al.Inhibition of drug-induced liver injury in mice using a positively charged peptide that binds DNAHepatol. Commun.5(10)1737-1754(2021).
[4].Boff, D., Russo, R.C., Crijns, H., et al.The therapeutic treatment with the GAG-binding chemokine fragment CXCL9(74-103) attenuates neutrophilic inflammation and lung dysfunction during Klebsiella pneumoniae infection in miceInt. J. Mol. Sci.23(11)6246(2022).
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2731 mL | 1.3656 mL | 2.7312 mL |
| 5 mM | 0.0546 mL | 0.2731 mL | 0.5462 mL |
| 10 mM | 0.0273 mL | 0.1366 mL | 0.2731 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。